- 0
Highlights & Basics
- Symptoms of acute conjunctivitis include an irritated red eye with a watery or purulent discharge.
- There are a range of causes of acute conjunctivitis, including allergy, bacterial or viral infection, mechanical stress, and irritation by toxic chemicals or drugs.
- Allergic conjunctivitis is usually bilateral with watery discharge and itching.
- Treatment for allergic conjunctivitis includes topical mast cell stabilizers and antihistamines; bacterial conjunctivitis treatment includes topical antibiotics; viral conjunctivitis requires symptomatic treatment.
- Bacterial and viral conjunctivitis is highly contagious; measures to prevent spread of infection should be considered.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Cheung, Albert Y. et al. Conjunctivitis preferred practice pattern. Ophthalmology. 2024 Feb 12;131(4): 134-204.[Full Text]
Castillo M, Scott NW, Mustafa MZ, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015 Jun 1;(6):CD009566.[Abstract][Full Text]
Chen YY, Liu SH, Nurmatov U, et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD001211.[Abstract][Full Text]
1. Cheung, Albert Y. et al. Conjunctivitis preferred practice pattern. Ophthalmology. 2024 Feb 12;131(4): 134-204.[Full Text]
2. Shields T, Sloan PD. A comparison of eye problems in primary care and ophthalmology practices. Fam Med. 1991 Sep-Oct;23(7):544-6.[Abstract]
3. Manners T. Managing eye conditions in general practice. BMJ. 1997 Sep 27;315(7111):816-7.[Abstract]
4. Royal College of General Practitioners, Royal College of Ophthalmologists. Ophthalmology for general practice trainees. London: Medical Protection Society; 2001.
5. Rietveld RP, ter Riet G, Bindels PJ, et al. Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of General Practice. BMC Fam Pract. 2007 Sep 16;8:54.[Abstract][Full Text]
6. Dart JK, Buckley RJ, Monnickendan M, et al. Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis. Trans Ophthalmol Soc UK. 1986;105(Pt 5):513-20.[Abstract]
7. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005 Jan;115(1):118-22.[Abstract]
8. Buckley RJ. Allergic eye disease: a clinical challenge. Clin Exp Allergy. 1998 Dec;28 Suppl 6:39-43.[Abstract]
9. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol. 2007 Feb;98(2):105-14; quiz 114-7, 152.[Abstract]
10. Choi SH, Bielory L. Late-phase reaction in ocular allergy. Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):438-44.[Abstract]
11. Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):779-89.e6.[Abstract][Full Text]
12. Bruschi G, Ghiglioni DG, Cozzi L, et al. Vernal keratoconjunctivitis: a systematic review. Clin Rev Allergy Immunol. 2023 Aug;65(2):277-329.[Abstract][Full Text]
13. Alemayehu AM, Yibekal BT, Fekadu SA. Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, June 2018. PLoS One. 2019;14(4):e0215528.[Abstract][Full Text]
14. Johnson D, Liu D, Simel D. Does this patient with acute infectious conjunctivitis have a bacterial infection?: the Rational Clinical Examination Systematic Review. JAMA. 2022 Jun 14;327(22):2231-7.[Abstract]
15. Choi CJ, Jakobiec FA, Zakka FR, et al. Conjunctival squamous cell neoplasia associated with ocular cicatricial pemphigoid. Ophthalmic Plast Reconstr Surg. 2017 Nov/Dec;33(6):e157-60.[Abstract][Full Text]
16. Stenson S, Newman R, Fedukowicz H. Laboratory studies in acute conjunctivitis. Arch Ophthalmology. 1982 Aug;100(8):1275-7.[Abstract]
17. Weiss A, Brinser J, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr Med. 1993 Jan;122(1):10-4.[Abstract]
18. Gigliotti F, Williams WT, Hayden FG. Etiology of acute conjunctivitis in children. J Pediatr. 1981 Apr;98(4):531-6.[Abstract]
19. Singh RB, Liu L, Anchouche S, et al. Ocular redness - I: etiology, pathogenesis, and assessment of conjunctival hyperemia. Ocul Surf. 2021 Jul;21:134-44.[Abstract][Full Text]
20. Ullman S, Roussel TJ, Culbertson WW, et al. Neisseria gonorrhoeae keratoconjunctivitis. Ophthalmology. 1987 May;94(5):525-31.[Abstract]
21. Johnson A. Ocular complications of cat scratch disease. Br J Ophthalmol. 2020 Dec;104(12):1640-6.[Abstract]
22. Durand ML, Barshak MB, Sobrin L. Eye infections. N Engl J Med. 2023 Dec 21;389(25):2363-75.[Abstract]
23. Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020 Jul-Sep;15(3):372-95.[Abstract][Full Text]
24. Kinchington PR, Turse SE, Kowalski RP, et al. Use of polymerase chain amplification reaction for the detection of adenoviruses in ocular swab specimens. Invest Ophthalmol Vis Sci. 1994 Nov;35(12):4126-34.[Abstract]
25. Hoffman J. Adenovirus: ocular manifestations. Community Eye Health. 2020;33(108):73-5.[Full Text]
26. Gordon YJ, Gordon RY, Romanowski E, et al. Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. Ophthalmology. 1993 Dec;100(12):1835-9; discussion 1839-40.[Abstract]
27. Azar MJ, Dhaliwal DK, Bower KS, et al. Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol. 1996 Jun;121(6):711-2.[Abstract]
28. Paley GL, Lubniewski AJ, Reidy JJ, et al. Toxic keratoconjunctivitis. Eye Contact Lens. 2018 Sep;44(Suppl 1):S8-15.[Abstract]
29. American Academy of Ophthalmology; EyeWiki. Preservatives in topical ophthalmic medications. Jan 2025 [internet publication].[Full Text]
30. Haider N, Neuman R, Foster CS, et al. Report on the sequence of DQB1*0301 gene in ocular cicatricial pemphigoid patients. Curr Eye Res. 1992 Dec;11(12):1233-8.[Abstract]
31. Ahmed AR, Foster S, Zaltas M, et al. Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11579-82.[Abstract][Full Text]
32. Ahn H, Ji YW, Jun I, et al. Effects of meibomian gland dysfunction and aqueous deficiency on friction-related disease. Ocul Surf. 2022 Oct;26:295-9.[Abstract]
33. Lin A, Ahmad S, Amescua G, et al. Blepharitis preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P50-86.[Abstract][Full Text]
34. Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P1-49.[Abstract][Full Text]
35. Woo YR, Kim HS. Deciphering childhood rosacea: a comprehensive review. J Clin Med. 2024 Feb 16;13(4):1126.[Abstract][Full Text]
36. Gupta S. Giant fornix syndrome. BMJ 2015 Dec 09;351:h6274.[Full Text]
37. Wu D, Daniel BS, Lai AJX, et al. Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol. 2022 Sep-Oct;67(5):1419-42.[Abstract]
38. Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Jan;84(1):139-47.[Abstract]
39. Dupuis P, Prokopich CL, Hynes A, et al. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5.[Abstract][Full Text]
40. O'Callaghan RJ. The pathogenesis of Staphylococcus aureus eye infections. Pathogens. 2018 Jan 10;7(1):9.[Abstract][Full Text]
41. Chen R, Yang J, Zhang C, et al. Global associations of air pollution and conjunctivitis diseases: a systematic review and meta-analysis. Int J Environ Res Public Health. 2019 Sep 28;16(19):3652.[Abstract][Full Text]
42. Bao J, Tian L, Meng Y, et al. Total IgE in tears accurately reflects the severity and predicts the prognosis of seasonal allergic conjunctivitis. Clin Transl Allergy. 2022 Mar;12(3):e12139.[Abstract][Full Text]
43. Fitch CP, Rapoza PA, Owens S. Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital. Ophthalmology. 1989 Aug;96(8):1215-20.[Abstract]
44. Nche EN, Okwen MM, Solomon A. Prevalence and clinical characteristics of vernal keratoconjunctivitis in sub-Saharan Africa. Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):423-9.[Abstract]
45. Addis H, Jeng BH. Vernal keratoconjunctivitis. Clin Ophthalmol. 2018;12:119-23.[Abstract][Full Text]
46. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye (Lond). 2003 Nov;17(8):886-92.[Abstract][Full Text]
47. American Academy of Ophthalmology; EyeNet Magazine. Chronic unilateral conjunctivitis: diagnosis and management. Nov 2020 [internet publication].[Full Text]
48. Lai NS, Tsai TY, Koo M, Lu MC. Association of rheumatoid arthritis with allergic diseases: a nationwide population-based cohort study. Allergy Asthma Proc. 2015 Sep-Oct;36(5):99-103.[Abstract]
49. Wollenberg A, Beck LA, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022 Mar;186(3):453-65.[Abstract][Full Text]
50. Centers for Disease Control and Prevention. Adult immunization schedule by age (addendum updated June 27, 2024). Nov 2024 [internet publication].[Full Text]
51. American Academy of Ophthalmology. EyeWiki: conjunctivitis. Jun 2024 [internet publication].[Full Text]
52. O'Brien TP, Jeng BH, McDonald M, et al. Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin. 2009 Aug;25(8):1953-61.[Abstract]
53. Leibowitz HW, Pratt MV, Flagstad IJ, et al. Human conjunctivitis. I. Diagnostic evaluation. Arch Ophthalmol. 1976 Oct;94(10):1747-9.[Abstract]
54. Cheung D, Bremner J, Chan JT. Epidemic kerato-conjunctivitis: do outbreaks have to be epidemic? Eye (Lond). 2003 Apr;17(3):356-63.[Abstract]
55. Sambursky R, Trattler W, Tauber S, et al. Sensitivity and specificity of the AdenoPlus test for diagnosing adenoviral conjunctivitis. JAMA Ophthalmol. 2013 Jan;131(1):17-22.[Abstract]
56. Sambursky R, Tauber S, Schirra F, et al. The RPS adeno detector for diagnosing adenoviral conjunctivitis. Ophthalmology. 2006 Oct;113(10):1758-64.[Abstract]
57. American Academy of Ophthalmology. Cornea/external disease summary benchmarks - 2024. Dec 2024 [internet publication].[Full Text]
58. Tanenbaum RE, Galor A, Dubovy SR, et al. Classification, diagnosis, and management of conjunctival lymphoma. Eye Vis (Lond). 2019 Jul 27:6:22.[Abstract][Full Text]
59. McGrath LA, Ryan DA, Warrier SK, et al. Conjunctival lymphoma. Eye (Lond). 2023 Apr;37(5):837-48.[Abstract][Full Text]
60. American Academy of Ophthalmology. Referral of persons with possible eye diseases or injury. Apr 2014 [internet publication].[Full Text]
61. American Academy of Ophthalmology. Pediatric eye evaluations preferred practice pattern. Dec 2022 [internet publication].[Abstract][Full Text]
62. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation preferred practice pattern®. Nov 2020 [internet publication].[Full Text]
63. American Academy of Ophthalmology. Frequency of ocular examinations. Mar 2015 [internet publication].[Full Text]
64. Bilkhu PS, Wolffsohn JS, Naroo SA, et al. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology. 2014 Jan;121(1):72-8.[Abstract][Full Text]
65. Castillo M, Scott NW, Mustafa MZ, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015 Jun 1;(6):CD009566.[Abstract][Full Text]
66. Mahvan TD, Buckley WA, Hornecker JR. Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1025-32.[Abstract]
67. Marini MC, Berra ML, Girado F, et al. Efficacy and toxicity evaluation of bepotastine besilate 1.5% preservative-free eye drops vs olopatadine hydrochloride 0.2% bak-preserved eye drops in patients with allergic conjunctivitis. Clin Ophthalmol. 2023;17:3477-89.[Abstract][Full Text]
68. Bonini S, Gramiccioni C, Bonini M, et al. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):446-9.[Abstract]
69. Bielory L, Katelaris CH, Lightman S, et al. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed. 2007 Aug 15;9(3):35.[Abstract][Full Text]
70. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):453-61.[Abstract]
71. Gonzalez-Estrada A, Reddy K, Dimov V, et al. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opin Pharmacother. 2017 Aug;18(11):1137-43.[Abstract]
72. Kam KW, Chen LJ, Wat N, et al. Topical olopatadine in the treatment of allergic conjunctivitis: a systematic review and meta-analysis. Ocul Immunol Inflamm. 2017 Oct;25(5):663-77.[Abstract]
73. Dou XY, Zhang W. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis. Int J Ophthalmol. 2023;16(2):286-92.[Abstract][Full Text]
74. Olopatadine for the treatment of allergic conjunctivitis: a review of the clinical efficacy, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2016. [Abstract][Full Text]
75. Schechter BA. Ketorolac tromethamine 0.4% as a treatment for allergic conjunctivitis. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):507-11.[Abstract]
76. Gong L, Sun X, Qu J, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther. 2012 Jun;34(6):1259-72.[Abstract]
77. Oner V, Türkcü FM, Taş M, et al. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol. 2012 Jul;56(4):312-8.[Abstract]
78. Liu RF, Wu XX, Wang X, et al. Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. Int Forum Allergy Rhinol. 2017 Apr;7(4):393-8.[Abstract][Full Text]
79. Wartna JB, Bohnen AM, Elshout G, et al. Symptomatic treatment of pollen-related allergic rhinoconjunctivitis in children: randomized controlled trial. Allergy. 2017 Apr;72(4):636-44.[Abstract]
80. Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol. 2007 Dec;91(12):1656-61.[Abstract][Full Text]
81. Swamy BN, Chilov M, McClellan K, et al. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiol. 2007 Sep-Oct;14(5):311-9.[Abstract]
82. Takamura E, Uchio E, Ebihara N, et al; Japanese Society of Allergology. Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int. 2017 Apr;66(2):220-9.[Abstract][Full Text]
83. Berger WE, Granet DB, Kabat AG. Diagnosis and management of allergic conjunctivitis in pediatric patients. Allergy Asthma Proc. 2017 Jan 1;38(1):16-27.[Abstract]
84. Chen YY, Liu SH, Nurmatov U, et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD001211.[Abstract][Full Text]
85. Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother. 2007 Aug;8(12):1903-21.[Abstract]
86. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract. 2001 Jun;51(467):473-7.[Abstract]
87. Honkila M, Koskela U, Kontiokari T, et al. Effect of topical antibiotics on duration of acute infective conjunctivitis in children: a randomized clinical trial and a systematic review and meta-analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2234459.[Abstract][Full Text]
88. Denis F, Chaumeil C, Goldschmidt P, et al. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. Eur J Ophthalmol. 2008 Nov-Dec;18(6):858-68.[Abstract]
89. Abelson MB, Heller W, Shapiro AM, et al; AzaSite Clinical Study Group. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008 Jun;145(6):959-65.[Abstract]
90. Protzko E, Bowman L, Abelson M, et al; AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9.[Abstract][Full Text]
91. Mah F. Bacterial conjunctivitis in pediatrics and primary care. Pediatr Clin North Am. 2006 May;53 Suppl 1:7-10; quiz 11, 13-5.[Abstract]
92. Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S1-6.[Abstract]
93. Silverstein BE, Morris TW, Gearinger LS, et al. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. Clin Ophthalmol. 2012;6:1987-96.[Abstract][Full Text]
94. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009 Mar;31(3):514-26.[Abstract]
95. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009 Sep;116(9):1615-23.e1.[Abstract]
96. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009 May;25(5):1159-69.[Abstract]
97. Sanfilippo CM, Allaire CM, DeCory HH. Besifloxacin ophthalmic suspension 0.6% compared with gatifloxacin ophthalmic solution 0.3% for the treatment of bacterial conjunctivitis in neonates. Drugs R D. 2017 Mar;17(1):167-75.[Abstract][Full Text]
98. O'Brien TP. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90.[Abstract]
99. Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol. 1989 May 15;107(5):511-4.[Abstract]
100. Kaufman HE. Ganciclovir: a promising topical antiviral gel for herpetic keratitis. Expert Rev Ophthal. 2009;4(4):367-75.[Full Text]
101. Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007 Dec;1(4):441-53.[Abstract][Full Text]
102. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26.[Abstract][Full Text]
103. Recommendations for the prevention of neonatal ophthalmia. Paediatr Child Health. 2002 Sep;7(7):480-3.[Abstract][Full Text]
104. Matejcek A, Goldman RD. Treatment and prevention of ophthalmia neonatorum. Can Fam Physician. 2013 Nov;59(11):1187-90.[Abstract][Full Text]
105. Liu SH, Hawkins BS, Ng SM, et al. Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis. Cochrane Database Syst Rev. 2022 Mar 3;3(3):CD013520.[Abstract][Full Text]
106. Ta CN, Raizman MB, Gross RD, et al. A prospective, randomized trial of povidone-iodine 0.6% and dexamethasone 0.1% ophthalmic suspension for acute bacterial conjunctivitis. Am J Ophthalmol. 2020 Jul;215:56-65.[Abstract][Full Text]
107. Alsudais AS, Alshehri WM, Alrehaili AM, et al. The efficacy and safety of dexamethasone intracanalicular insert use in patients with chronic seasonal/perennial allergic conjunctivitis: a systematic review and meta-analysis. Clin Ophthalmol. 2024 Sep 21:18:2657-66.[Abstract][Full Text]
108. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998 Feb 15;57(4):735-46.[Abstract]
109. Butt AL, Chodosh J. Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea. 2006 Feb;25(2):199-202.[Abstract]
110. Colón LE. Keratoconjunctivitis due to adenovirus type 8: report on a large outbreak. Ann Ophthalmol. 1991 Feb;23(2):63-5.[Abstract]
111. Ankers HE, Klapper PE, Cleator GM, et al. The role of a rapid diagnostic test (adenovirus immune dot blot) in the control of an outbreak of adenovirus type-8 keratoconjunctivitis. Eye. 1993;7(Pt 3 Suppl):15-7.[Abstract]
112. Jackson WB, Davis PL, Groh V, et al. Adenovirus type 19 keratoconjunctivitis in Canada. Can J Ophthalmol. 1975 Jul;10(3):326-33.[Abstract]
113. Richmond S, Burman R, Crosdale E, et al. A large outbreak of keratoconjunctivitis due to adenovirus type 8. J Hyg (Lond). 1984 Oct;93(2):285-91.[Abstract]
114. Hyde KJ, Berger ST. Epidemic keratoconjunctivitis and lacrimal excretory system obstruction. Ophthalm. 1988 Oct;95(10):1447-9.[Abstract]
115. Hammer LH, Perry HD, Donnenfeld ED, et al. Symblepharon formation in epidemic keratoconjunctivitis. Cornea. 1990 Oct;9(4):338-40.[Abstract]
